<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03269396</url>
  </required_header>
  <id_info>
    <org_study_id>15-005642</org_study_id>
    <nct_id>NCT03269396</nct_id>
  </id_info>
  <brief_title>Laryngeal Allograft Transplantation</brief_title>
  <official_title>A Prospective Nonrandomized Study of Laryngeal Allograft Transplantation Clinical Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proposed study is to obtain safety and efficacy data on human laryngeal&#xD;
      allograft transplantation in an effort to safely use these procedures as a viable&#xD;
      reconstructive option for patients with severe laryngeal or laryngotracheal incompetence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe laryngeal or laryngotracheal incompetence without other reconstructive&#xD;
      options will be considered for cadaveric laryngotracheal transplantation. Data will be&#xD;
      collected from 10 patients and will include length of hospital stay, short-term&#xD;
      complications, long-term complications, hospital readmission, return trips to the operating&#xD;
      room (OR), rejection episodes and severity, swallowing function, ability to have tracheotomy&#xD;
      tube decannulated, voice parameters, pulmonary function, development of anti-donor&#xD;
      antibodies, and quality of life scores.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2033</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival of the allograft at the one-year visit.</measure>
    <time_frame>1 year</time_frame>
    <description>Survival of the allograft as indicated by histological rejection grading.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Swallowing without aspiration at the one-year visit.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voice Evaluation</measure>
    <time_frame>1 year</time_frame>
    <description>Standard voice evaluation will include voice recordings, acoustic and aerodynamic measurements as compared to baseline measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>1 year</time_frame>
    <description>Pulmonary function values within normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to have tracheotomy tube decannulated</measure>
    <time_frame>1 year</time_frame>
    <description>Ability to have tracheotomy tube decannulated after successful capping trials.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Larynx Stenosis</condition>
  <condition>Larynx Disease</condition>
  <condition>Laryngectomy</condition>
  <condition>Larynx</condition>
  <condition>Larynx Fracture</condition>
  <arm_group>
    <arm_group_label>Larynx Allograft Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cadaveric laryngotracheal transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Larynx Allograft Transplantation</intervention_name>
    <description>This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.</description>
    <arm_group_label>Larynx Allograft Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Potential subjects for this study include patients with severe laryngeal dysfunction or a&#xD;
        previous laryngectomy. For the purposes of this study, severe laryngeal dysfunction is&#xD;
        defined as the loss of normal laryngeal function resulting in significant dysphonia,&#xD;
        dysphagia, or dyspnea.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18 years and older&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  One of the following:&#xD;
&#xD;
               -  Severe laryngeal dysfunction as described above&#xD;
&#xD;
               -  Laryngeal stenosis&#xD;
&#xD;
               -  5 years or longer s/p definitive management for head and neck cancer&#xD;
&#xD;
               -  Laryngeal cancer requiring total laryngectomy in a patient already on&#xD;
                  immunosuppression&#xD;
&#xD;
               -  Low-grade chondrosarcoma requiring total laryngectomy&#xD;
&#xD;
          -  Ability to obtain informed consent from the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Poor surgical candidacy secondary to poor physical/mental health as determined by a&#xD;
        pre-operative medical evaluation&#xD;
&#xD;
        General medical status&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Any systemic disease which would alter life expectancy&#xD;
&#xD;
               -  Active neoplastic disease, not considered yet to be cured (Exceptional cases will&#xD;
                  be considered in case by case discussion)Less than 5 years s/p definitive&#xD;
                  management for cancer&#xD;
&#xD;
               -  Cancer within the last 5 years (Exceptional cases will be considered in case by&#xD;
                  case discussion)&#xD;
&#xD;
               -  Obesity (Body Mass Index &gt;29 - 30)(Exceptional cases will be considered on a case&#xD;
                  by case basis)&#xD;
&#xD;
               -  Cachexia (BMI&lt;18)(Exceptional cases will be considered on a case by case basis)&#xD;
                  Significant renal dysfunction (Creatinine clearance &lt; 50 ml/min.)&#xD;
&#xD;
               -  Significant hepatic dysfunction&#xD;
&#xD;
               -  Significant kidney damage&#xD;
&#xD;
               -  Unmanageable infections&#xD;
&#xD;
               -  Unable to participate in preoperative exercise training&#xD;
&#xD;
               -  Unable to be weaned to equal or less than 10 mg/day of steroids&#xD;
&#xD;
               -  Untreatable cardiac disease&#xD;
&#xD;
               -  Active neuromuscular disease&#xD;
&#xD;
               -  History of recurrent aspiration or active, unmanageable Gastro-Esophageal Reflux&#xD;
&#xD;
               -  Patients with active connective tissue diseases (exceptions to be considered in a&#xD;
                  case by case basis)&#xD;
&#xD;
               -  Patients unable to achieve &gt; 600 feet in a 6 minute walk test (exceptions to be&#xD;
                  considered in a case by case basis)&#xD;
&#xD;
               -  Patients considered having active immunodeficiency disorders (exceptions to be&#xD;
                  considered in a case by case basis)&#xD;
&#xD;
               -  Multiple co-morbidities that would make transplantation prohibitively risky&#xD;
&#xD;
          -  Psychosocial parameters&#xD;
&#xD;
               -  Severe mental retardation, psychosis, depression or organic brain syndrome&#xD;
&#xD;
               -  Uncontrolled diabetes mellitus. Once HbA1C &lt; 7, reevaluate for candidacy.&#xD;
&#xD;
               -  Active substance use within 6 months&#xD;
&#xD;
               -  Active smoking within 6 months&#xD;
&#xD;
               -  Active alcoholism within 6 months&#xD;
&#xD;
               -  Inability to comply with transplant-related management and medical follow-up&#xD;
&#xD;
               -  Any other circumstances that deem the candidate high risk from a psychosocial&#xD;
                  perspective&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David G Lott</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>David G. Lott, M.D.</investigator_full_name>
    <investigator_title>Consultant-Department of Otolaryngology Head &amp; Neck Surgery/Audiology</investigator_title>
  </responsible_party>
  <keyword>severe laryngotracheal dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

